AVVantgarde Bio is a gene therapy startup that has developed two adeno-associated viral (AAV)-based platforms with increased transfer capabilities to enable the delivery of large genes.
Gene therapy based on AAV vectors has proven effective for several forms of genetic blindness, however the small vector payload may limit their further application. The company’s two AAV-based platforms have expanded transfer capability that enable the delivery of large genes.
The company aims to initially focus on using it approach to launch clinical trials of gene therapies for inherited retinal disorders.
Founded in 2021, AAVantgarde Bio originates from research activities performed at Tigem (Telethon Institute of Genetics and Medicine) in Naples, Italy. Co-founder Professor Alberto Auricchio, is described by the company as a pioneer in the field of gene therapy.
Subscribe for alerts on new companies featured on Startups.Bio